Risk factors

SELLAS Life Sciences Group (SLS) risk factors

Item 1A of every SELLAS Life Sciences Group, Inc. 10-K on file, and what changed from one year to the next.

Open SLS in Gloomberb →
  • FY2025 10-K risk factors

    75 risks, 6 new, 8 dropped, 11 reworded since the prior year. Future Phase 3 trials may face FDA diversity-plan requirements, while enrollment delays could raise costs and extend timelines.

    Filed Mar 19, 2026
  • FY2024 10-K risk factors

    77 risks. The company relies heavily on clinical success and financing for its lead drug candidates, GPS and SLS009. Operations depend significantly on third-party manufacturers, license agreements with MSK and GenFleet, and navigating complex regulatory pathways.

    Filed Mar 20, 2025